Avelumab & Bladder Cancer

In the context of Avelumab & Bladder Cancer, Avelumab has FDA and EMA approvals in advanced Bladder Cancer, historically as post‑platinum therapy and currently as first‑line maintenance after platinum‑based chemotherapy in patients without progression (1, 2, 5, 6). Avelumab as a first-line maintenance treatment presents an appealing choice for these patients (3)

Clinical data

The randomized clinical phase III trial, known as NCT02603432 or JAVELIN Bladder 100, was

• groundbreaking as it was the first to establish the effectiveness of switch maintenance therapy for patients with…